Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM08RE5)

• Drug Name: TAK-280 Drug Info
• Synonyms: MVC-280

Indication

Disease Entry	ICD 11	Status	REF
Aggressive cancer	2A00-2F9Z	Phase 2	[1]

• Cross-matching ID: TTD Drug ID: DM08RE5

Molecule-Related Drug Atlas

Drug(s) Targeting B7 homolog 3 (CD276)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Omburtamab I-131	DMPDA17	Neuroblastoma	2D11.2	Phase 2/3	[2]
131 I-omburtamab	DM12UX6	Brain and central nervous system tumour	2A00.11	Phase 2/3	[3]
Omburtamab	DMTIESG	Neuroblastoma	2D11.2	Phase 2/3	[4]
Enoblituzumab	DMDS20X	Prostate cancer	2C82.0	Phase 2	[5]
DS-7300	DMK4VY9	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[6]
Omburtamab I-124	DMPLBDF	Glioma	2A00.0	Phase 1/2	[2]
MGC018	DM1KZW0	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[7]
MGD009	DME4B8I	Solid tumour/cancer	2A00-2F9Z	Phase 1	[5]
MGA271	DM2PVLH	Metastatic cancer	2D50-2E2Z	Phase 1	[8]
124I-8H9	DM5ZC0E	Glioblastoma multiforme	2A00.0	Phase 1	[9]

Drug(s) Targeting T-cell surface glycoprotein CD3 (CD3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Blinatumomab	DMGECIJ	Acute lymphoblastic leukaemia	2A85	Approved	[10]
Mosunetuzumab	DM15ZIB	Follicular lymphoma	2A80	Approved	[11]
Epcoritamab	DMEX86V	Diffuse large B-cell lymphoma	2A81	Approved	[12]
Talquetamab	DMXRENI	Multiple myeloma	2A83	Approved	[13]
Elranatamab	DMG1MW2	Multiple myeloma	2A83	Approved	[14]
Nivatrotamab	DMAOUZV	Small-cell lung cancer	2C25.Y	Phase 2	[15]
Otelixizumab	DMFNDBC	Type-1 diabetes	5A10	Phase 2	[16]
Plamotamab	DMOV28A	Diffuse large B-cell lymphoma	2A81	Phase 2	[17]
Odronextamab	DMP6NVV	B-cell non-hodgkin lymphoma	2B33.5	Phase 2	[18]
Tarlatamab	DME33OU	Small-cell lung cancer	2C25.Y	Phase 2	[19]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
B7 homolog 3 (CD276)	TT6CQUM	CD276_HUMAN	Not Available	[1]
T-cell surface glycoprotein CD3 (CD3)	TTUN7MC	NOUNIPROTAC	Not Available	[1]

References

• [1] ClinicalTrials.gov (NCT05220098) A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-280 in Patients With Unresectable Locally Advanced or Metastatic Cancer. U.S.National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] IntraOmmaya compartmental radioimmunotherapy using 131 I-omburtamab-pharmacokinetic modeling to optimize therapeutic index. Eur J Nucl Med Mol Imaging. 2021 Apr;48(4):1166-1177.
• [4] Mast cell proliferation in the cerebrospinal fluid after intraventricular administration of anti-B7H3 immunotherapy. Cancer Immunol Immunother. 2021 Feb 3.
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] Clinical pipeline report, company report or official report of Daiichi Sankyo.
• [7] Clinical pipeline report, company report or official report of MacroGenics.
• [8] T Cell Coinhibition and Immunotherapy in Human Breast Cancer. Discov Med. 2012 October; 14(77): 229-236.
• [9] National Cancer Institute Drug Dictionary (drug id 722029).
• [10] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [11] Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. NPJ Syst Biol Appl. 2020 Aug 28;6(1):28.
• [12] Clinical pipeline report, company report or official report of Genmab.
• [13] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761342
• [14] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761345
• [15] Clinical pipeline report, company report or official report of Y-mAbs Therapeutics.
• [16] Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes.Diabetes Care.2014 Oct;37(10):2746-54.
• [17] Plamotamab (XmAb(?)13676) for Ibrutinib- refractory CXCR4-mutated extramedullary Waldenstr?m macroglobulinemia. Leuk Lymphoma. 2022 Mar;63(3):738-742.
• [18] Odronextamab, a human CD20*CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 2022 May;9(5):e327-e339.
• [19] Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study. J Clin Oncol. 2023 Jun 1;41(16):2893-2903.